Banmédica S.A.

What it is

Banmédica runs four lines of business: private health insurance (isapre), hospital and clinic care, international operations, and a small property-and-administration arm. It has served more than 2.1 million insurance members and nearly four million patients across 13 hospitals and 143 medical centres.

Its main subsidiaries include Isapre Banmédica, Vida Tres, Clínica Santa María, the mobile-rescue unit Help, and Colombia’s Colmédica and AliánSalud. The group has historically operated in Chile, Colombia, and Peru, though it has since wound down its Peruvian presence.

Who owns it

In September 2017, UnitedHealth Group — the world’s largest health insurer — agreed to buy Banmédica from its two controlling shareholders, Empresas Penta and Fernández León, for CLP 1.7 trillion (US$1.8 bn). UnitedHealth ultimately acquired a 96.8% stake, completing the deal in January 2018.

In late November 2025, UnitedHealth agreed to sell Banmédica to Brazilian private equity firm Patria Investments for $1 billion. Chilean media reported that Patria is partnering with local private equity firm Linzor Capital, adding domestic regulatory and operational expertise to the consortium.

The deal, signed in late November 2025, remains subject to regulatory approvals in Chile and Colombia.

Who runs it

The Wikipedia entry names Gonzalo Ibáñez Langlois as chairman and Carlos Kubik Castro as CEO during the pre-acquisition period; both positions are expected to be reviewed under the new Patria ownership. UnitedHealth’s own leadership shift — Stephen Hemsley returning as group CEO — directly shaped the decision to exit Latin America and sell Banmédica as part of a broader simplification drive.

Current Banmédica-level executive appointments under Patria have not yet been disclosed in available sources.

The money, in plain words

In 2018 — the last full year of filed public accounts — Banmédica brought in CLP 1.63 trillion (US$1.8 bn) (~$1.77bn), up 6.2% from the year before (our calculation). It kept CLP 42.8bn (US$47 mn) (~$46.6m) as profit after all costs, a net profit margin of 2.6% (our calculation) — thin by global standards, reflecting the high cost of running hospitals and paying insurance claims in a regulated market.

For every peso of owners’ equity, it generated about 12.4 cents of annual profit — a return on equity of 12.4% (our calculation), moderate but respectable for a capital-heavy health system. UnitedHealth ultimately booked a $1.2 billion write-down on Banmédica, reflecting the gap between the $2.8bn it paid in 2018 and the $1.0bn it recovered in 2025 — a reminder that healthcare regulation and currency moves can erode even a well-run business.

What it is doing now

UnitedHealth’s sale of Banmédica marks the final step in the U.S. giant’s complete exit from Latin America. At the time of the deal, Banmédica operated 1.7 million health-plan members, seven hospitals, and 47 medical centres across Chile and Colombia.

Banmédica will join Patria’s growing healthcare holdings, which include Zentria — a large integrated healthcare operator in Colombia — and Athena Saúde, a Brazilian hospital group. The addition of Banmédica positions Patria as one of Latin America’s most influential private healthcare investors.

What to watch

• Regulatory sign-off: the deal still requires green lights from competition authorities in both Chile and Colombia; any condition or delay would reshape the ownership timeline.
• New management team: Patria has not yet named a CEO or board for the post-transition company; the first executive appointments will signal strategic direction.
• Chile’s isapre crisis: Chile’s private health-insurance system has been under deep political pressure for several years; how Banmédica navigates any structural reform will be the central financial test for its new owners.
• Colombia growth: Patria already owns Zentria in Colombia, raising the question of whether the two platforms will be merged or run separately — a decision that could sharply change Banmédica’s competitive footprint.

This is news, not investment advice.